Samsung Biologics has extended its collaboration with LigaChem Biosciences to provide ADC services targeting the growing global ADC market

The partnership will involve supporting LigaChem’s ADC programs at Samsung’s new dedicated ADC facility, focusing on solid tumors

LigaChem emphasized that the partnership will enhance the ADC supply chain and competitiveness, leveraging Samsung Biologics’ expertise to accelerate pipeline development and deliver innovative treatments

LigaChem Biosciences, expects to receive royalties this year to support R&D and aims to develop 15+ clinical pipelines in the next five years

Samsung Biologics will conduct joint projects at its new ADC facility in Songdo, Incheon, equipped with a 500-liter conjugation reactor and purification line